Musculoskeletal Therapeutics
1. Bextra patent expiration
Treatment: Signs and symptoms of osteoarthritis and adult rheumatoid arthritis and treatment of primary dysmenorrhea
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5633272 | GD SEARLE | Substituted isoxazoles for the treatment of inflammation |
Feb, 2015
(10 years ago) | |
Drugs and Companies using VALDECOXIB ingredient
Market Authorisation Date: 16 November, 2001
Dosage: TABLET
More Information on Dosage
BEXTRA family patents
2. Boniva patent expiration
Treatment: Treatment and prevention of osteoporosis; Treatment and prevention of osteoporosis in postmenopausal women by once-monthly oral administration of ibandronate sodium monohydrate equivalent to 150mg of ...
BONIVA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6143326 | HOFFMANN LA ROCHE | Oral pharmaceutical preparation containing ibandronat |
Apr, 2017
(8 years ago) | |
| US7718634 | HOFFMANN LA ROCHE | Method of treatment using bisphosphonic acid |
May, 2023
(2 years ago) | |
| US6294196 | HOFFMANN LA ROCHE | Pharmaceutical composition containing diphosphonic acid or salt thereof |
Oct, 2019
(6 years ago) | |
| US7410957 | HOFFMANN LA ROCHE | Method of treatment using bisphosphonic acid |
May, 2023
(2 years ago) | |
| US7192938 | HOFFMANN LA ROCHE | Method of treatment using bisphosphonic acid |
May, 2023
(2 years ago) | |
Drugs and Companies using IBANDRONATE SODIUM ingredient
Market Authorisation Date: 16 May, 2003
Dosage: TABLET
How can I launch a generic of BONIVA before it's drug patent expiration?
More Information on Dosage
BONIVA family patents
3. Boniva patent
expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5662918 | ROCHE | Pharmaceutical agents containing diphosphonic acids and salts thereof |
Sep, 2014
(11 years ago) | |
Drugs and Companies using IBANDRONATE SODIUM ingredient
Market Authorisation Date: 06 January, 2006
Dosage: INJECTABLE
How can I launch a generic of BONIVA before it's drug patent expiration?
More Information on Dosage
BONIVA family patents
4. Cymbalta patent expiration
Treatment: Management of fibromyalgia (fm); Method of treating anxiety
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6596756 (Pediatric) | LILLY | Treatment of fibromyalgia |
Mar, 2020
(5 years ago) | |
| US5508276 | LILLY | Duloxetine enteric pellets |
Jul, 2014
(11 years ago) | |
| US6596756 | LILLY | Treatment of fibromyalgia |
Sep, 2019
(6 years ago) | |
| US5023269 | LILLY | 3-aryloxy-3-substituted propanamines |
Jun, 2013
(12 years ago) | |
|
US5023269 (Pediatric) | LILLY | 3-aryloxy-3-substituted propanamines |
Dec, 2013
(12 years ago) | |
|
US5508276 (Pediatric) | LILLY | Duloxetine enteric pellets |
Jan, 2015
(10 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-617) | Nov 19, 2012 |
| New Indication(I-632) | Nov 04, 2013 |
| Pediatric Exclusivity(PED) | Apr 18, 2016 |
| M(M-61) | Oct 18, 2015 |
| New Patient Population(NPP) | Apr 20, 2023 |
Drugs and Companies using DULOXETINE HYDROCHLORIDE ingredient
Market Authorisation Date: 03 August, 2004
Dosage: CAPSULE, DELAYED REL PELLETS
How can I launch a generic of CYMBALTA before it's drug patent expiration?
More Information on Dosage
CYMBALTA family patents
5. Qutenza patent expiration
Treatment: Method of using capsaicin in combination with a gel composition for removal of capsaicin from a treatment area or unintended area
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8263059 | AVERITAS | Compositions and kits for the removal of irritating compounds from bodily surfaces |
Sep, 2023
(2 years ago) | |
| US10869827 | AVERITAS | Compositions and kits for the removal of irritating compounds from bodily surfaces |
Sep, 2023
(2 years ago) | |
| US6239180 | AVERITAS | Transdermal therapeutic device and method with capsaicin and capsaicin analogs |
Nov, 2016
(9 years ago) | |
| US8889113 | AVERITAS | Compositions and kits for the removal of irritating compounds from bodily surfaces |
Sep, 2023
(2 years ago) | |
| US10463598 | AVERITAS | Compositions and kits for the removal of irritating compounds from bodily surfaces |
Sep, 2023
(2 years ago) | |
| US9226903 | AVERITAS | Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer or the system and use of said back layer |
Dec, 2028
(2 years from now) | |
| US10034841 | AVERITAS | Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer of the system and use of said back layer |
Sep, 2025
(4 months ago) | |
| US8821920 | AVERITAS | Therapeutic patch for transdermal delivery of capsaicin |
Mar, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 16, 2014 |
| Orphan Drug Exclusivity(ODE) | Nov 16, 2016 |
| New Indication(I-838) | Jul 17, 2023 |
Drugs and Companies using CAPSAICIN ingredient
NCE-1 date: 16 November, 2013
Market Authorisation Date: 16 November, 2009
Dosage: PATCH
More Information on Dosage
QUTENZA family patents
6. Sohonos patent expiration
Treatment: Reduction of heterotopic ossification in patients with fibrodysplasia (myositis) ossificans progressiva; Reduction of heterotopic ossification in patients with fibrodysplasia ossificans (myositis) pro...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11622959 | IPSEN | Methods for treating heterotopic ossification |
Jun, 2037
(11 years from now) | |
| US10864194 | IPSEN | Methods for treating heterotopic ossification |
Jun, 2037
(11 years from now) | |
| US10292954 | IPSEN | Composition and method for muscle repair and regeneration |
Aug, 2031
(5 years from now) | |
| US9789074 | IPSEN | Composition and method for muscle repair and regeneration |
Aug, 2031
(5 years from now) | |
| US9314439 | IPSEN | Composition and method for muscle repair and regeneration |
Aug, 2031
(5 years from now) | |
| US12023312 | IPSEN | Composition and method for muscle repair and regeneration |
Aug, 2031
(5 years from now) | |
| US12201614 | IPSEN | Methods for treating heterotopic ossification |
Jun, 2037
(11 years from now) | |
| US12458626 | IPSEN | NA |
Jun, 2037
(11 years from now) | |
| US12138245 | IPSEN | Methods for treating heterotopic ossification |
Jun, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 16, 2028 |
| Orphan Drug Exclusivity(ODE-439) | Aug 16, 2030 |
Drugs and Companies using PALOVAROTENE ingredient
NCE-1 date: 17 August, 2027
Market Authorisation Date: 16 August, 2023
Dosage: CAPSULE
More Information on Dosage
SOHONOS family patents
7. Vioxx patent expiration
Treatment: Relief of the signs and symptoms of osteoarthritis; Relief of the signs and symptoms of rheumatoid arthritis in adults; Management of acute pain in adults; Treatment of primary dysmenorrhea; Acute tre...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5691374 | MERCK | Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors |
May, 2015
(10 years ago) | |
|
US5474995 (Pediatric) | MERCK | Phenyl heterocycles as cox-2 inhibitors |
Dec, 2013
(12 years ago) | |
|
US6239173 (Pediatric) | MERCK | 3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5H)-furanone as a cox-2 inhibitor |
Dec, 2013
(12 years ago) | |
|
US5691374 (Pediatric) | MERCK | Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors |
Nov, 2015
(10 years ago) | |
| US5474995 | MERCK | Phenyl heterocycles as cox-2 inhibitors |
Jun, 2013
(12 years ago) | |
|
US6063811 (Pediatric) | MERCK | Compositions for a once day treatment of cyclooxygenase-2 mediated diseases |
Nov, 2017
(8 years ago) | |
| US6239173 | MERCK | 3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5H)-furanone as a cox-2 inhibitor |
Jun, 2013
(12 years ago) | |
| US6063811 | MERCK | Compositions for a once day treatment of cyclooxygenase-2 mediated diseases |
May, 2017
(8 years ago) | |
Drugs and Companies using ROFECOXIB ingredient
Market Authorisation Date: 20 May, 1999
Dosage: TABLET; SUSPENSION
How can I launch a generic of VIOXX before it's drug patent expiration?
More Information on Dosage
VIOXX family patents